Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health

source extracted confidence: high 2026-04-09
#united-states #humans #covid-19 #fatty-acids-omega-3 #cardiovascular-diseases

Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health

Rodriguez et al., 2022 | Nutrients | Meta Analysis

Citation

Rodriguez Daniel, Lavie Carl J, ... Milani Richard V. Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health. Nutrients. 2022-Dec-03;14(23). doi:10.3390/nu14235146

Abstract

Twenty percent of deaths in the United States are secondary to cardiovascular diseases (CVD). In patients with hyperlipidemia and hypertriglyceridemia, studies have shown high atherosclerotic CVD (ASCVD) event rates despite the use of statins. Given the association of high triglyceride (TG) levels with elevated cholesterol and low levels of high-density lipoprotein cholesterol, the American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol guidelines recommend using elevated TGs as a "risk-enhancing factor" for ASCVD and using omega 3 fatty acids (Ω3FAs) for patients with persistently elevated severe hypertriglyceridemia. Ω3FA, or fish oils (FOs), have been shown to reduce very high TG levels, hospitalizations, and CVD mortality in randomized controlled trials (RCTs). We have published the largest meta-analysis to date demonstrating significant effects on several CVD outcomes, especially fatal myocardial infarctions (MIs) and total MIs. Despite the most intensive research on Ω3FAs on CVD, their benefits have been demonstrated to cluster across multiple systems and pathologies, including autoimmune diseases, infectious diseases, chronic kidney disease, central nervous system diseases, and, most recently, the COVID-19 pandemic. A review and summary of the controversies surrounding Ω3FAs, some of the latest evidence-based findings, and the current and most updated recommendations on Ω3FAs are presented in this paper.

Key Findings

A review and summary of the controversies surrounding Ω3FAs, some of the latest evidence-based findings, and the current and most updated recommendations on Ω3FAs are presented in this paper.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population hyperlipidemia and hypertriglyceridemia
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • United States
  • Humans
  • COVID-19
  • Fatty Acids, Omega-3
  • Cardiovascular Diseases
  • Cholesterol, HDL
  • Triglycerides
  • Cholesterol
  • Hypertriglyceridemia
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hyperlipidemias
  • Myocardial Infarction

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Meta-Analysis, Journal Article, Review
  • Vertical: omega-3-cardiovascular

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09